Leo Pharma Relies on Biologics and Grows 13% in 2021 in Spain

Leo Pharma increases its profitability in Spain. The Spanish subsidiary of the dermatological laboratory of Danish origin achieved revenues of $83.8 million (€78 million) in 2021, which translates into an increase of 12.6% compared to 2020, as Nuno Bras, CEO of Leo Pharma Iberia said. The company recognizes that this result is also in line with the evolution that the launch of its new biologic treatment for atopic dermatitis, tralokinumab, is having in the market.

Leo Pharma Spain invests $2.15 million (€2 million) a year in research and development (R&D). The laboratory’s research studies in Spain place it, on a global scale, among the top five countries in the group, at the same level as the research activity carried out in Germany or the United States. Leo Pharma’s research in Spain has included three clinical trials of tralokinumab, in which 19 Spanish hospitals in seven autonomous communities have participated.

Read more about Leo Pharma and find the latest business headlines of the day with the Born2Invest mobile app.

Leo Pharma recorded a turnover of $1.44 billion (€1.34 billion) in 2021

On a global scale, the company recorded a turnover of $1.44 billion (€1.34 billion) in 2021, compared with $1.46 billion (€1.36 billion) in 2020. “The results obtained are highly satisfactory and place us in an optimal position to continue moving towards our 2030 strategy, focused on strengthening our position as a benchmark in medical dermatology,” says Bras. The company expects to achieve international sales of more than $5.4 billion (€5 billion) by 2030. Leo Pharma currently has a workforce of more than 5,800 employees worldwide, 145 of whom are in Spain.

Leo Pharma is a pharmaceutical group, founded more than 110 years ago in Copenhagen (Denmark), which since its inception has been committed to the research and development of drugs specializing in dermatology and thrombosis.

The company has a strategic focus on drugs for skin diseases such as atopic dermatitis, psoriasis, skin infections, as well as seventy years of expertise in research, development, and production of low molecular weight heparins that have contributed to improve the prevention and treatment of thrombosis.

Leo Pharma Spain relies on biologics and grows by 13% in 2021, to 78 million

Currently, Leo Pharma is the only laboratory specialized in medical dermatology that covers the entire spectrum of severity of two very prevalent topical diseases such as atopic dermatitis and psoriasis.

“Medical dermatology is one of the three fastest-growing medical therapeutic areas, along with oncology and neurology; in the next decade, the market is expected to double reaching a value of more than €50 billion,” acknowledges the CEO of Leo Pharma Iberia. “In this sense, our Strategy 2030 is the roadmap with which we aspire to become one of the top five players in the next decade,” added Bras.

The company is owned by the Leo Foundation, which holds a majority stake, although private equity firm Nordic Capital is also a shareholder. Moreover, Leo Pharma has several projects such as Leo Pharma Open Innovation, which gives researchers around the world access to scientific resources to develop research and trials without giving up intellectual property; Leo Innovation Lab, developing digital solutions for patients; and Leo Science&Tech Hub, which explores investment opportunities in cutting-edge science and technology with relevance to dermatology.

__

(Featured image by pasja1000 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.